




Sociedad Española
de Reumatología -
Colegio Mexicano
de Reumatología

Reumatología Clínica

www.reumatologiaclinica.org



Original article

Utility of neutrophil/albumin ratio and C-reactive protein/albumin ratio as novel inflammatory markers in Behcet's disease



Doaa E. Kamal^a, Rabab S. Zaghlol^{a,b,*}, Marwa H.S. Hussien^c, Wafaa K. Makarm^a

^a Rheumatology and Rehabilitation Department, Faculty of Medicine, Zagazig University, Egypt

^b Physical Medicine and Rehabilitation Department, Security Forces Hospital, Makkah, Saudi Arabia

^c Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Egypt

ARTICLE INFO

Article history:

Received 27 October 2021

Accepted 18 May 2022

Keywords:

Behcet

C-reactive protein to albumin ratio

Neutrophil to albumin ratio

ABSTRACT

Introduction and objectives: Behcet's disease (BD) is an autoimmune systemic inflammatory disease, and its exact pathogenesis is unknown. There are currently no specific tests to evaluate the disease activity of BD, making its management more difficult. This study aims to determine the neutrophil/albumin ratio (NAR) and C-reactive protein (CRP) to albumin ratio (CAR) and investigate their associations with clinical findings in patients with BD and to determine optimum cutoff levels of CAR and NAR.

Methods: The study included 75 consecutively recruited patients with BD with a mean age of 33.29 ± 6.23 years and disease duration of 7.21 ± 4.64 years, as well as 75 healthy participants. Clinical characteristics and laboratory data were obtained. Disease activity was assessed using the BD current activity form score (BDCAF).

Results: NAR and CAR were elevated in patients with BD compared with those of healthy controls (NAR: 1.08 ± 0.34 vs. 0.607 ± 0.06 , CAR: 2.49 ± 1.73 vs. 0.39 ± 0.142 ; $p < 0.0001$), as well as in active BD versus inactive BD. Both NAR and CAR were significantly correlated with CRP, active uveitis, and BDCAF score ($p \leq 0.05$). In patients with active BD, the cutoff value of NAR was >0.9744 (sensitivity: 89.74%, specificity: 80.56%), while that of CAR was >2.04 (sensitivity: 74.36%, specificity: 83.33%).

Conclusions: NAR and CAR are both elevated in patients with BD and may contribute to its active state. NAR and CAR can be feasible and inexpensive markers for predicting BD activity.

© 2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Utilidad de la relación neutrófilos/albúmina y la relación proteína C reactiva/albúmina como nuevos marcadores inflamatorios en la enfermedad de Behçet

RESUMEN

Introducción y objetivos: La enfermedad de Behçet (EB) es una enfermedad inflamatoria sistémica autoinmune y se desconoce su patogenia exacta. Actualmente no existen pruebas específicas para evaluar la actividad de la EB, lo que dificulta su manejo. El objetivo de este estudio es determinar la proporción neutrófilos/albúmina (NAR) y de proteína C reactiva (CRP)/albúmina (CAR) e investigar sus asociaciones con los hallazgos clínicos en pacientes con EB y determinar los niveles de corte óptimos de CAR y NAR.

Métodos: El estudio incluyó a 75 pacientes con EB reclutados consecutivamente con una edad media de $33,29 \pm 6,23$ años y una duración de la enfermedad de $7,21 \pm 4,64$ años, así como a 75 participantes sanos. Se obtuvieron características clínicas y datos de laboratorio. La actividad de la enfermedad se evaluó utilizando la puntuación del formulario de actividad actual de la EB (BD Current Activity Form [BDCAF]).

Palabras clave:

Behçet

Proporción proteína C reactiva/albúmina

Relación neutrófilos/albúmina

* Corresponding author.

E-mail address: rababzaghlol@yahoo.com (R.S. Zaghlol).

Resultados: NAR y CAR estaban elevados en pacientes con EB en comparación con controles sanos (NAR: $1,08 \pm 0,34$ vs. $0,607 \pm 0,06$, CAR: $2,49 \pm 1,73$ vs. $0,39 \pm 0,142$; $p < 0,0001$), así como en pacientes EB activos versus EB inactivos. Tanto la NAR como la CAR se correlacionaron significativamente con la PCR, la uveítis activa y la puntuación BDCAF ($p \leq 0,05$). En pacientes con EB activa, el valor de corte de NAR fue $> 0,9744$ (sensibilidad: 89,74%, especificidad: 80,56%), mientras que el de CAR fue $> 2,04$ (sensibilidad: 74,36%, especificidad: 83,33%).

Conclusiones: NAR y CAR están elevados en pacientes con EB y pueden contribuir a su estado activo. NAR y CAR pueden ser marcadores factibles y económicos para predecir la actividad de EB.

© 2022 Elsevier España, S.L.U.

y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

Introduction

Behcet's disease (BD) is a chronic multisystemic disease of unknown etiology. It can affect a variety of organs and can go into remission and relapse. Characteristic BD features include recurrent oral, genital, and mucosal ulceration, uveitis, and cutaneous lesions. The neurological, cardiovascular, gastrointestinal, and musculoskeletal systems may also be involved.^{1–3} Neutrophil hyperfunction, vasculitis, and autoimmune reactions appear to be responsible for the disease.^{4,5}

Several laboratory tests have been studied for their ability to reflect disease activity, evaluate treatment efficacy, or predict future complications of BD, but no particular test has been found to detect disease activity.^{6–9} Nevertheless, the C-reactive protein (CRP) to albumin ratio (CAR) has been proposed as a better indicator of inflammatory response compared with CRP or albumin alone.^{10,11} CAR is a well-established predictor of a variety of diseases, including rheumatoid arthritis, BD uveitis, heart disease, and various cancers.^{12–14} Furthermore, higher levels of CAR are also associated with poor prognosis and worse treatment outcomes in systemic diseases.^{15,16}

The neutrophil/albumin ratio (NAR) has been reported as a new inflammatory indicator in severe infection, cancer, and schizophrenia. In patients with cancer, a higher level of NAR was found to represent an increased inflammatory state, which poorly affects prognosis and treatment response.¹⁷ Neutrophils, the key components of the innate immune system, are activated and recruited to the target tissue by inflammatory mediators due to the chronic inflammatory status of BD, causing damage and organ dysfunction.¹⁸ Hypoalbuminemia in BD reflects the underlying active inflammatory state; the decrease in hepatic albumin production (a negative acute-phase reactant) may be caused by increased inflammatory mediators.¹⁹ However, NAR has not been studied in BD.

Thus, we aim to examine the value of the CAR and NAR in patients with BD in terms of their associations with clinical characteristics, as well as to determine their optimum cut-off levels. In this study, we hypothesized that CAR and NAR are associated with disease activity and can serve as novel inflammatory markers in BD.

Methods

Study design

This case-control study was conducted in the Rheumatology & Rehabilitation Departments, Faculty of Medicine, Zagazig University.

Study population

The study included 75 patients with BD who were routinely followed up at the Department of Rheumatology, Rehabilitation,

and Physical Medicine, Faculty of Medicine, Zagazig University, from January 2021 to May 2021. BD diagnosis was made according to the revised International Criteria for Behcet's Disease 2010 criteria.²⁰ The study also included a control group of 75 healthy adults of the same age and gender. We excluded patients with other autoimmune diseases or systemic disorders (i.e., malignancy, diabetes mellitus, heart failure, hepatic dysfunction, renal dysfunction, acute infection, and chronic infection). Informed consent was obtained from each subject before their participation in the study. Approval was obtained from the ethics committee of the university (registration number: ZU-IRB 6614/19-9-2019). The study was conducted in accordance with the ethical standards of the Declaration of Helsinki.

Data collection

Patient data were gathered from their medical records, including demographic data, such as name, age, sex, and disease duration. Furthermore, the same rheumatologist carried out a comprehensive history and clinical examination in all patients.

Determination of disease activity

Disease activity during the past 4 weeks was evaluated using the validated Turkish version of the BD Current Activity Form (BDCAF). The presence of active disease was defined as having a BDCAF score of ≥ 2 out of 12.²¹

Laboratory investigations

A complete blood count including the differential count, erythrocytes sedimentation rate (ESR), CRP, and serum albumin were obtained from patients with BD and healthy controls. The white blood cell (WBC), neutrophil, lymphocyte, and platelet counts were recorded. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), NAR, and CAR were calculated from these parameters.

In our hospital, complete blood counts were determined using the Sysmex KX-21 hematology analyzer (Sysmex Corporation, America), and albumin was measured using the automated clinical chemistry analyzer Cobas Integra 400 plus (Roche Diagnostics, Deutschland). CRP levels were measured using automated nephelometry BN Prospec (Siemens, UK), and ESR was analyzed in the 1st hour using Westergren's method.

Statistical analysis

All data were collected, tabulated, and statistically analyzed using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA 2011). Quantitative data were expressed as the mean \pm standard deviation and median (range), and qualitative data were expressed as absolute frequencies (number) and relative frequencies (percentage). Comparisons of normally distributed continuous variables were

Table 1
Clinical characteristics of patients with BD.

Variables	Behcet patients (n = 75)
Disease duration (year)	7.21 ± 4.64, 7 (1–24)
Oral ulcer	58 (77.3%)
Genital ulcers	52 (69.3%)
Papulopustular lesions	3 (4%)
Erythema nodosum	2 (2.6%)
Pathergy test	4 (5.3%)
Articular manifestations	22 (29.3%)
Ocular affection	38 (50.6%)
Active Uveitis	29 (38.6%)
Anterior uveitis	4 (5.3%)
Posterior uveitis	34 (45.3%)
Pan uveitis	3 (4%)
Arterial involvement	1 (1.33%)
Venous involvement	34 (45.3%)
Deep venous thrombosis	6 (8%)
Superficial thrombophlebitis	7 (9.33%)
Neurological involvement	5 (6.6%)
Pulmonary involvement	1 (1.33%)
Cardiovascular involvement	11 (14.7%)
BDCAF score, median (range)	1.94 ± 1.005, 2 (1–4)
Active disease, n (%)	39 (52%)
Treatment	
Colchicine	28 (37.3%)
Dapsone	3 (4%)
Corticosteroids	53 (70.6%)
Azathioprine	35 (46.7%)
Cyclophosphamide	6 (8%)
Cyclosporine	4 (5.3%)
Chlorambucil	1 (1.33%)
Methotrexate	5 (6.7%)
Infliximab	17 (22.6%)
Adalimumab	22 (29.3%)
Anticoagulants	6 (8%)

Values are stated as number and percentage *n* (%), mean ± Sd or median (range), BDCAF: Bechet's disease current activity form.

carried out using independent samples Student's *t*-test, while the Mann–Whitney *U* test was used for non-normally distributed data. Percent of categorical variables were compared using Chi-square test or Fisher's exact test when appropriate. Relationships of the NAR and CAR ratio with various parameters of BD were assessed by calculating Pearson's and Spearman's correlation coefficients. To differentiate between patients with active and inactive BD, the optimal cut-off values of the NAR, CAR, CRP, ESR, NLR, and PLR with the maximum sensitivity and specificity were calculated via receiver operating characteristic (ROC) curve analysis. The *-*statistic was used to compare the areas under the ROC curves (AUCs). *p*-Values of ≤0.05 were statistically significant, whereas *p*-values of >0.05 were considered statistically insignificant.

Results

The main clinical characteristics of the 75 patients with BD are summarized in Table 1. Oral ulceration (77.3%) and genital ulceration (69.3%) were the most common clinical features of patients with BD, whereas pulmonary and arterial involvement was the least common (1.33%). The mean duration of BD was 7.21 ± 4.64 years. The median disease activity score assessed via BDCAF was 2 (range: 1–4). Accordingly, 39 patients were considered to have active BD.

Our study included 75 patients with BD with a mean age of 34.29 ± 6.23 years (24 females, 51 males) and 75 healthy controls matched for age and sex (*p* > 0.05). Patients with BD had significantly increased levels of ESR, CRP, albumin, WBCs, neutrophil, NLR, and PLR compared with those of controls (*p* ≤ 0.05). Furthermore, patients with BD also had significantly increased NAR (1.08 ± 0.34; *p* < 0.0001) and CAR (2.49 ± 1.73; *p* < 0.0001) compared with those of controls. However, the two groups did not differ significantly in

Table 2
Demographic and laboratory results of Behcet patients and controls.

Variables	Behcet patients (n = 75)	Control (n = 75)	<i>p</i> value
Age (years)	33.29 ± 6.23 34 (22–57)	32.96 ± 5.33 33 (24–54)	0.16 ^a
Gender			
Female	24 (32%)	27 (36%)	0.61 ^c
Male	51 (68%)	48 (64%)	
BMI (kg/m ²)	24.47 ± 2.43 24.2 (21.4–31.8)	24.62 ± 2.05 24.5 (21.4–32.2)	0.68 ^a
ESR, mm/h	28 (3–130)	18 (10–28)	0.001^{b*}
CRP, mg/ dL	10.3 ± 7.2 10 (0.12 – 33.6)	1.71 ± 0.63 1.6 (0.3 – 3.5)	0.0001^{a*}
Albumin (g/dl)	4.22 ± 0.34 4.2 (3.49–4.81)	4.46 ± 0.19 4.39 (3.64–4.8)	0.001^{a*}
HGB	12.84 ± 0.65 12.7 (11.9–15)	12.88 ± 0.65 12.9 (12.3–14.7)	0.68 ^a
WBCS, (x103/mm ³)	8.16 ± 1.704 7.9 (4.2–15.4)	5.89 ± 1.17 5.6 (4.2–8.8)	< 0.0001^{a*}
Platelets, (x103/mm ³)	272 (201 –402)	265 (228–320)	0.13 ^b
Neutrophil, × (x103/mm ³)	4.551 ± 1.36	2.725 ± 0.30	< 0.0001^{a*}
Lymphocyte, × (x103/mm ³)	4.4 (2.5–7.6) 2.23 ± 0.531	2.7 (2.2–3.4) 2.15 ± 0.34	0.289 ^a
NLR	2.2 (1.4–3.2) 2.109 ± 0.67	2.1 (1.3–2.9) 1.31 ± 0.28	0.0001^{a*}
PLR	2.04 (0.8–5.2) 122.17 (52.64–202.66)	1.27 (0.16–2) 116.1 (79.31–168.8)	0.0397^{b*}
CAR	2.49 ± 1.73 2.4 (0.02–7.3)	0.39 ± 0.142 0.37 (0.074–0.755)	0.0001^{a*}
NAR	1.08 ± 0.34 1.1 (0.31–3.2)	0.607 ± 0.06 0.6 (0.33–0.48)	0.0001^{a*}

All values are presented a number and percentage *n* (%), mean ± Sd or median (range), number (%) or mean ± SD.

^a Independent *t*-test.

^b Mann–Whitney *U* test.

^c Chi-square test.

HG: hemoglobin, WBC: white blood cells, CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin ratio, PLR: platelet/lymphocyte ratio, NLR: neutrophil/lymphocyte ratio, *p* ≤ 0.05 = significant.

the other parameters, such as body mass index, hemoglobin level, and platelet and lymphocyte counts (*p* > 0.05) (Table 2).

When we compared patients in the active (*n* = 39) and inactive BD (*n* = 36) state, significant differences were found in the ESR, CRP, WBC count, neutrophil count, serum albumin, and NLR (*p* = 0.004, *p* < 0.001, *p* = 0.0039, *p* = 0.001, *p* = 0.002, and *p* = 0.0008, respectively). Patients with active BD (*n* = 39) had a significantly higher NAR compared with those with inactive BD (*n* = 6, *p* < 0.0001). Furthermore, patients with active BD had a significantly increased CAR compared with those with inactive BD (*p* < 0.0001) (Table 3).

Gender and smoking habits were not significantly associated with either NAR or CAR among patients with BD (*p* > 0.05). However, NAR levels tended to be higher in patients with BD with oral ulceration, articular involvement, and ocular involvement (i.e., active uveitis) (*p* = 0.0416, *p* = 0.0493, and *p* = 0.0108, respectively) compared with those without involvement. Similarly, a significant difference regarding CAR was found in patients with BD with ocular involvement (active uveitis) (*p* = 0.0349) compared with those without active uveitis. Thus, NAR was closely linked to the presence of oral ulcerations and articular manifestations, whereas CAR was not. Otherwise, neither NAR nor CAR levels were affected by the presence of vascular, pulmonary, cardiovascular, or neurological involvements in BD (*p* > 0.05) (Table 4).

The ROC curve analyses for CAR and NAR as well as other inflammatory markers were performed to evaluate the disease activity in patients with BD included in the study. Specifically, CAR was compared with the CRP and albumin levels as presented in Table 5. The AUC of the NAR (0.849, 95% confidence interval

Table 3
Comparison of parameters according to disease activity in BD.

Variables	Active n = 39	Inactive n = 36	T test	P value
Age	34.82 ± 8.85 35 (22-57)	34.44 ± 5.72 34.5 (26-48)	t = 0.21	0.82 ^a
Gender (female/male)	11/28	13/23	0.537	0.46 ^c
Disease duration	6.46 ± 4.24 6 (1-14)	8.36 ± 4.72 8 (2-24)	t = 1.836 u=3.48	0.0704 ^a .004^{b*}
ESR (mm/hour)	31 (5-130)	20 (3-65)	t = 5.66	<.0001^{a*}
CRP (mg/L)	14.19 ± 6.97 14.2 (0.2-33.6)	6.231 ± 4.92 6.1 (0.12-26.8)	t = 5.66	<.0001^{a*}
WBCS, (x103/mm ³)	8.68 ± 1.95 8.5 (5-15.4)	7.58 ± 1.088 7.5 (4.2-10)	t = 2.9822	0.003^{a*}
Neutrophil, × (x103/mm ³)	5.21 ± 1.45 5.1 (3-7.6)	3.83 ± 0.7 3.7 (2.5-5.8)	t = 5.149	0.001^{a*}
HGB	12.856 ± 0.609 12.7 (11.9-14.6)	12.85 ± 0.682 12.7 (12-15)	t = 0.04	0.96 ^a
Lymphocyte, × (x103/mm ³)	2.31 ± 0.61 2.3 (1.5-3.2)	2.13 ± 0.387 2.1 (1.4-2.8)	t = 1.511 u=1.67	.135 ^a 0.094 ^b
Platelets, (x103/mm ³)	268 (201-402)	248.5 (201-316)	t=3.18	0.002^{a*}
Albumin (g/dl)	4.16 ± 0.28 4.1 (3.49-4.6)	4.38 ± 0.31 4.2 (3.7-4.81)	t = 3.484	0.0008^a
NLR	2.349 ± 0.734 2.2 (1.6-5.2)	1.847 ± 0.475 1.7 (0.8-2.9)	u = 1.33	0.18 ^b
PLR	123.63 (52.641-202.66)	116.84 (80-158.64)	t = 5.6	<0.00001^{a*}
CAR	3.26 ± 1.56 3.2 (0.04-7.3)	1.4659 ± 1.182 1.3 (0.02-6.3)	t = 5.73	<0.0001^{a*}
NAR	1.236 ± 0.3149 1.2 (0.65-3.2)	0.882 ± 0.2028 0.86 (0.31-1.26)		<0.0001^{a*}

All values are presented a number and percentage *n* (%), mean ± Sd or median (range), number (%) or mean ± SD.

^a Independent *t*-test.

^b Mann–Whitney *U* test.

^c Chi-square test.

WBC: white blood cells, CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin ratio, PLR: platelet/lymphocyte ratio, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, NLR: neutrophil/lymphocyte ratio.

[CI]: 0.747–0.921, $p < 0.0001$) and CAR (0.777, 95% CI: 0.666–0.865, $p < 0.001$) in patients with BD were higher than those of albumin, neutrophil count, CRP, and ESR. Fig. 1 depicts the discriminatory value of these indicators in relation to the BDCAF score.

In patients with BD, NAR had significant positive correlations with the presence of active uveitis ($r = 0.31$, $p < 0.006$), oral ulcerations ($r = 0.244$, $p = 0.034$), joint involvement (0.236, $p = 0.041$), BDCAF score ($r = 0.59$, $p < 0.001$), ESR ($r = 0.153$, $p = 0.028$), CRP ($r = 0.230$, $p = 0.04$), neutrophil count ($r = 0.69$, $p < 0.001$), NLR ($r = 0.67$, $p < 0.0001$), and CAR ($r = 0.28$, $p = 0.014$). Moreover, CAR also had significant positive correlations with the presence of active uveitis ($r = 0.25$, $p = 0.03$), BDCAF score ($r = 0.541$, $p < 0.001$), CRP ($r = 0.49$, $p < 0.0001$), and NAR ($r = 0.28$, $p = 0.014$). Furthermore, both CAR ($r = -0.369$, $p = 0.011$) and NAR ($r = -0.451$, $p = 0.0004$) had significant negative correlations with serum albumin. Other parameters such as age, disease duration, mucocutaneous involvement, vascular involvement, and PLR were not correlated with either NAR or CAR ($p > 0.05$) (Table 6, Fig. 2).

Discussion

The principal finding of the present study was that patients with BD had higher NAR and CAR values than healthy controls especially during the active stage of the disease, even in those of treated patients with BD. Moreover, comparisons showed that these two parameters were positively correlated with CRP, active uveitis, and BDCAF score. Previous studies have shown that CAR levels correlated with the activity of different autoimmune and rheumatic diseases.²² However, no studies have associated CAR and NAR with the different clinical manifestations and disease activity in patients with BD.

Although acute-phase protein, immunoglobulin, complement, autoantibody, lymphocyte, surface indicator, and cytokine levels

are used as indicators of BD activity, there is no specific indicator for disease activation.⁶ Previously, the total BDCAF score was found to correlate well with both ESR and CRP levels, but there are still conflicting findings regarding the relationship between these parameters and clinical disease activity in BD.²³ Recently, studies have suggested that CAR and NAR are reliable biomarkers of inflammation, and a combination of inflammatory markers including CAR and NAR can be used to indicate increased inflammatory status.²⁴ Besides CAR and NAR, we also evaluated ESR, CRP, NLR, and PLR, all of which have been investigated in several studies.

Similarly, in a study comparing the inflammatory markers between patients with acutely exacerbated and remitted schizophrenia and healthy controls,²⁴ CAR and NAR levels were found to be significantly higher in patients with schizophrenia than in control subjects. The authors proposed that a combination of inflammatory markers including CAR and NAR could be used to reflect the increased inflammatory status in schizophrenia. In accordance with this, a retrospective study of 32 patients with and 32 healthy controls found that CAR had the highest correlation with disease activity in patients with Takayasu arteritis.²²

In our study, serum NAR was significantly increased in patients with active BD ($n = 39$) compared with those with inactive BD ($n = 36$, $p < 0.0001$). Furthermore, patients with active BD had a significantly increased CAR compared with those with inactive BD ($p < 0.0001$). Both CAR and NAR also had significant positive correlations with the BDCAF score.

Interestingly, NAR was significantly correlated with NLR ($p \leq 0.05$), whereas PLR was not correlated with either NAR or CAR ($p > 0.05$). Significant differences in NLR values were also found in patients with active BD versus those with inactive BD; this is consistent with a previous Egyptian study, which concluded that NLR was higher in patients with active BD than in those with inactive BD ($p < 0.01$). Although both NLR and PLR were correlated with BDCAF,

Table 4
Comparison of CAR and NAR according to BD characteristics.

Variables	CAR, mean \pm SD	p value	NAR, mean \pm SD	p value
<i>Gender</i>				
Female (24)	2.628 \pm 1.85	<i>p</i> = 0.60	0.998 \pm 0.248	<i>p</i> = 0.16
Male (51)	2.401 \pm 1.758		1.117 \pm 0.376	
<i>Smoking</i>				
Yes (22)	2.156 \pm 1.56	<i>p</i> = 0.2922	1.076 \pm 0.3752	<i>p</i> = 0.93
No (53)	2.623 \pm 1.87		1.083 \pm 0.2703	
<i>Oral ulcer</i>				
Present (58)	2.628 \pm 1.79	<i>p</i> = 0.17	1.120 \pm 0.351	<i>p</i> = 0.0416*
Absent (17)	1.947 \pm 1.67		0.936 \pm 0.182	
<i>Genital ulcers</i>				
Present (52)	2.298 \pm 1.78	<i>p</i> = 0.204	2.156 \pm 1.5625	<i>p</i> = 0.26
Absent (23)	2.871 \pm 1.75		2.623 \pm 1.8716	
<i>Rash</i>				
Present (5)	1.858 \pm 1.59	<i>p</i> = 0.21	1.085 \pm 0.3127	<i>p</i> = 0.94
Absent (70)	2.580 \pm 1.80		1.077 \pm 0.3506	
<i>Articular manifestations</i>				
Present (22)	2.854 \pm 1.84	<i>p</i> = 0.28	1.209 \pm 0.5081	<i>p</i> = 0.049*
Absent (53)	2.345 \pm 1.759		1.034 \pm 0.2573	
<i>Active uveitis</i>				
Present (29)	2.905 \pm 1.617	<i>p</i> = 0.0349*	1.183 \pm 0.239	<i>p</i> = 0.0108*
Absent (46)	2.007 \pm 1.855		0.966 \pm 0.402	
<i>Venous involvement</i>				
Present (28)	2.723 \pm 1.694	<i>p</i> = 0.31	1.087 \pm 0.281	<i>p</i> = 0.85
Absent (47)	2.298 \pm 1.84		1.072 \pm 0.384	
<i>Superficial thrombophlebitis</i>				
Present (7)	2.397 \pm 1.6626	<i>p</i> = 0.841	0.967 \pm 0.222	<i>p</i> = 0.123
Absent (68)	2.496 \pm 1.8282		1.111 \pm 0.366	
<i>Cardiovascular involvement</i>				
Present (11)	2.489 \pm 1.776	<i>p</i> = 0.976	1.115 \pm 0.396	<i>p</i> = 0.69
Absent (64)	2.471 \pm 1.796		1.072 \pm 0.337	
<i>Neuro-Bechet</i>				
Present (5)	2.068 \pm 1.634	<i>p</i> = 0.441	1.012 \pm 0.324	<i>p</i> = 0.504
Absent (70)	2.536 \pm 1.806		1.089 \pm 0.347	

All values are stated as mean and SD, CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin ratio, NLR: neutrophil/lymphocyte ratio.

* Significant \leq 0.05.

Table 5
ROC curve analysis of NAR and CAR and other inflammatory markers to differentiate between active and inactive Behcet disease.

Variable	Cut-off value	Sensitivity	Specificity	AUCs	95% CI	p value
Neutrophils	>4.5	74.36	77.78	0.762	0.650–0.853	<0.001*
Albumin	\leq 4.16	64.10	86.11	0.733	0.618–0.829	<0.002*
CAR	>2.0444	74.36	83.33	0.777	0.666–0.865	<0.001*
NAR	>0.9744	89.74	80.56	0.849	0.747–0.921	<0.0001*
CRP (mg/dl)	>9.3	71.79	86.11	0.759	0.647–0.851	<0.001*
ESR (mm/hr.)	>29	61.54	72.22	0.679	0.562–0.783	0.0045*

CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin Ratio, CR: C-reactive protein, ESR: erythrocyte sedimentation rate.

* Significant \leq 0.05.

the correlation of NLR with BDCAF was significantly stronger than that of PLR.²⁵

Moreover, a recent study revealed that active BD was associated with higher NLR and PLR, but only a slight correlation between NLR and BD activity. Those authors recommended further separate investigations of PLR and NLR and their relationship with various manifestations of the disease, since NLR and PLR seem to have specific associations with BD activity.²⁶

Similarly, two studies have found CAR to be a useful biomarker in describing the activity of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.^{26,27} This finding is consistent with other studies investigating the correlation of CAR and NAR with other inflammatory mediators in various diseases.²⁴ On the other hand, in a cross-sectional study of 121 patients with

rheumatoid arthritis assessing the relationship of CAR with disease activity, quality of life, and physical function, a significant but weak correlation between CAR and disease activity was found among the enrolled patients.¹¹

Patients with BD with oral ulcerations had significantly higher articular involvement, ocular involvement (active uveitis), and NAR than in those without involvement. Similarly, patients with BD with active uveitis had a considerable difference in CAR value compared with those without active uveitis. Thus, NAR was closely associated with the presence of oral ulcerations and articular manifestations, whereas CAR was not. However, no studies have been conducted to compare CAR and NAR based on BD characteristics.

In our study, ROC interpretation revealed that the NAR and CAR values in patients with active BD had an AUC of 0.849 and 0.777,




Fig. 1. (a) ROC curve of NAR in predicting active BD. (b) ROC curve of CAR in predicting active BD. (c) ROC curve of NAR and CAR versus other inflammatory markers in predicting active BD.

respectively, which are higher than those of albumin, neutrophil count, CRP, and ESR. The cut-off value of NAR in our study was >0.9744, and this had a sensitivity of 89.74% (the highest sensitivity percentage among patients with active BD) and a specificity of 80.56%. On the other hand, CAR had a cut-off value of >2.0444, with a sensitivity and specificity of 74.36% and 83.33%, respectively. To date, no studies have previously provided cut-off values or AUC for BD activity.

However, it was previously reported that the AUC of CAR was 0.801 when used to predict the existence of uveitis among patients with BD; this was remarkably high compared with the AUCs of other inflammatory biomarkers.²⁸ In line with this, another study in patients with systemic sclerosis identified the AUC of CAR to be 0.788 ($p=0.000$), which was significant with a 95% CI of 0.651–0.925.²⁹

Notably, CAR is accepted as an important parameter in the prognosis and follow-up of many diseases. It is used as a prognostic marker for disease activity and mortality, especially in inflammatory conditions, such as sepsis and septic shock.¹⁵ The novelty of this study lies in the comparison of CAR and NAR in patients with

BD with different clinical and laboratory findings as well as disease activity.

BD is characterized by chronic relapsing episodes and may cause significant morbidity and mortality due to ocular, vascular, and neurological involvements. Early prediction of disease activity may enable clinicians to aggressively manage the disease to prevent the occurrence of complications.³⁰ However, further research is still required to establish the optimal laboratory tests for predicting BD activity.

Limitations

Our study had some limitations. First, this study was a single-center case-control study. Furthermore, the duration of the treatment in each patient could have changed CAR and NAR levels; this should be investigated in future studies to confirm their diagnostic potential. Nevertheless, large multicenter prospective studies are needed to verify our findings.

Table 6
Correlations of CAR and NAR with patients' characteristics in BD.

Variable	CAR (n = 75)		NAR (n = 75)	
	r	p value	r	p value
Age	0.19	0.102	0.18	0.12
Disease duration	0.22	0.0578	0.11	0.34
Mucocutaneous manifestations	0.161	0.173	0.201	0.083
Oral ulceration	0.049	0.67	0.244	0.034*
Articular manifestations	0.109	0.35	0.236	0.041*
Active uveitis	0.25	0.03*	0.31	0.006*
Vascular involvement	0.11	0.34	0.03	0.79
BDCAF score	0.541	<0.001*	0.59	<0.001*
CRP (mg/dl)	0.49	<0.0001*	0.230	0.04*
ESR (mm/h)	0.22	0.057	0.153	0.028*
Albumin (g/dl)	-0.369	.0011*	-0.451	.0004*
WBCS, ($\times 10^3/\text{mm}^3$)	0.096	0.442	0.192	.098
Neutrophil, ($\times 10^3/\text{mm}^3$)	0.19	0.102	0.69	<0.001*
Lymphocyte, ($\times 10^3/\text{mm}^3$)	0.21	.0705	0.133	0.255
Platelets, ($\times 10^3/\text{mm}^3$)	0.10	0.36	0.145	0.214
NLR	0.020	0.86	0.67	<0.0001*
PLR	0.12	0.305	0.004	0.970
NAR	0.28	0.014*	-	-
CAR	-	-	0.28	0.014*

BDCAF: Bechet's disease current activity form; ESR: erythrocyte sedimentation rate; CR: C-reactive protein; CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin ratio, PLR: platelet to lymphocyte ratio, NLR: neutrophil/lymphocyte ratio.

* p significant ≤ 0.05 .




Fig. 2. (a) The correlation between NAR and BDCAF in patients with BD. (b) Correlation between CAR and BDCAF in patients with BD. (c) Correlation of NAR and CRP in patients with BD (d) Correlation of NAR and CAR in patients with BD.

Conclusions

NAR and CAR are elevated in patients with BD and may contribute to the active disease state. Our results suggested that NAR and CAR are feasible and inexpensive tools for predicting BD activity.

Key points

- CAR and NAR are novel inflammatory markers in BD and are associated with disease activity.
- CAR and NAR are feasible and inexpensive tools for predicting BD activity.
- CAR and NAR can predict the critical inflammatory state relevant to the pathological process in BD.

Authors' contributions

All authors have contributed to designing the study, collecting and analyzing, interpretation of data, and preparing and revising the manuscript. Design of the study: DK, RZ, MH and WM. Recruitment of patients: DK, RZ, MH and WM. Data collection: DK, RZ, MH and WM. Manuscript preparation and revision: DK, RZ, MH and WM. All co-authors have approved the final version.

Each author made significant individual contributions to the following: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting of the article, critical revisions for important intellectual content, and approval of the final manuscript. Each author believes that the manuscript represents honest work. All authors contributed actively to the study.

Ethical statement

Informed consents were obtained from all patients. An approval was obtained from the ethics committee of Faculty of Medicine, Zagazig University, and the approval number was ZU-IRB 6614/19-9-2019 and the study was conducted in conformity with Declaration of Helsinki.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest

There is no conflict of interest to the author's knowledge.

Acknowledgement

None declared.

References

- Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behçet's disease pathophysiology: a contemporary review. *Auto Immun Highlights*. 2016;7:4. <http://dx.doi.org/10.1007/s13317-016-0074-1>. Epub PMID: 26868128; PMCID: 2016 Feb 12 PMC4751097.
- Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. *Nat Rev Rheumatol*. 2018;14:107–19. <http://dx.doi.org/10.1038/nrrheum.2017.208>. Epub 2018 Jan 3. Erratum in: *Nat Rev Rheumatol*. 14 (2):119. PMID: 2018 Jan 24 29296024.
- Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet's disease. *Autoimmun Rev*. 2012;11:687–98. <http://dx.doi.org/10.1016/j.autrev.2011.11.026>. PMID: 2011 Dec 11 22197900.
- Zhang Z, Su Q, Zhang L, Yang Z, Qiu Y, Mo W. Diagnostic value of hemoglobin and neutrophil-to-lymphocyte ratio in Behçet Disease. *Medicine (Baltimore)*. 2019;98:e18443. <http://dx.doi.org/10.1097/MD.00000000000018443>. PMID: 31876725; PMCID: PMC6946511.
- Balkarli A, Kucuk A, Babur H, Erbasan F. Neutrophil/lymphocyte ratio and mean platelet volume in Behçet's disease. *Eur Rev Med Pharmacol Sci*. 2016;20:3045–50. PMID: 27460734.
- Avci A, Avci D. Serum prolactin levels in Behçet's disease. Is there a relationship between Behçet's disease and prolactin as in other autoimmune diseases? *Acta Dermatovenerol Croat*. 2013;21:52–3. PMID: 23683488.
- Ygündüz M, Bavbek N, Öztürk M, Kaftan O, Kosar A, Kirazli S. Serum beta 2-microglobulin reflects disease activity in Behçet's disease. *Rheumatol Int*. 2002;22:5–8. <http://dx.doi.org/10.1007/s00296-002-0180-4>.
- Calis M, Ates F, Yazici C, Kose K, Kirnap M, Demir M, et al. Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet's disease. *Rheumatol Int*. 2005;25:452–6. <http://dx.doi.org/10.1007/s00296-005-0612-z>.
- Gasparyan AY, Ayyvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. *Ann Lab Med*. 2019;39:345–57. <http://dx.doi.org/10.3343/alm.2019.39.4.345>.
- Afifi N, Medhat M, Abdel Ghani B, Mohamed Ali Hassan AM, Behiry HGE. Value of albumin-fibrinogen ratio and CRP-albumin ratio as predictor marker of disease activity in Egyptian RA patients, correlated with musculoskeletal sonography. *Open Access Rheumatol*. 2020;12:241–8. <http://dx.doi.org/10.2147/OARRR.S268668>. PMID: 33173359; PMCID: PMC7646446.
- Sunar I, Ataman Ş. Serum C-reactive protein/albumin ratio in rheumatoid arthritis and its relationship with disease activity, physical function, and quality of life. *Arch Rheumatol*. 2020;35:247–53. <http://dx.doi.org/10.46497/ArchRheumatol.2020.7456>. PMID: 32851374; PMCID: PMC7406154.
- Tsujino T, Komura K, Hashimoto T, Muraoka R, Satake N, Matsunaga T, et al. C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma – a data from multi-institutional study in Japan. *Urol Oncol*. 2019;37. <http://dx.doi.org/10.1016/j.urolonc.2019.04.002>. 812.e1–812.e8. Epub PMID: 2019 Apr 30 3031053528.
- Bozkurt E, Muhafiz E, Sengul D, Uçak T, Atum M. Can the CRP/albumin ratio be used as a new indicator of activation in patients with uveitis? *Ocul Immunol Inflamm*. 2020;3:1–6. <http://dx.doi.org/10.1080/09273948.2020.1714061>. Epub ahead of print. PMID: 32125910.
- Kayabasi S, Hizli O, Cayir S. A novel predictor parameter for active recurrent aphthous stomatitis: C-reactive protein to albumin ratio. *Cureus*. 2019;11:e5965. <http://dx.doi.org/10.7759/cureus.5965>. PMID: 31803551; PMCID: PMC6874286.
- Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. *PLoS ONE*. 2018;8:e59321. <http://dx.doi.org/10.1371/journal.pone.0059321>. PMID: 23555017; PMCID: 2013 Mar 12 PMC3595283.
- Li N, Tian GW, Wang Y, Zhang H, Wang ZH, Li G. Prognostic role of the pretreatment c-reactive protein/albumin ratio in solid cancers: a meta-analysis. *Sci Rep*. 2017;7:41298. <http://dx.doi.org/10.1038/srep41298>. PMID: 28128229; PMCID: PMC 5269668.
- Gong Y, Li D, Cheng B, Ying B, Wang B. Increased neutrophil percentage-to-albumin ratio is associated with all-cause mortality in patients with severe sepsis or septic shock. *Epidemiol Infect*. 2020;148:e87. <http://dx.doi.org/10.1017/S0950268820000771>. PMID: 32238212; PMCID: PMC7189348.
- Selders GS, Fetz AE, Radic MZ, Bowlin GL. An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. *Regen Biomater*. 2017;4:55–68. <http://dx.doi.org/10.1093/rb/rbw041>.
- Ataş N, Bubaoglu H, Demirel E, Çelik B, Bilici Salman R, Satiş H, et al. Use of prognostic nutritional index in the evaluation of disease activity in patients with Behçet's disease. *Eur J Rheumatol*. 2020;7:99–104. <http://dx.doi.org/10.5152/eurjrheum.2020.20010>. Epub PMID: 32716840; PMCID: 2020 Jul 21 PMC7431357.
- Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *J Eur Acad Dermatol Venereol*. 2014;28:338–47. <http://dx.doi.org/10.1111/jdv.12107>. Epub 2013 Feb 26.
- Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gonçalves CR. Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. *Clin Rheumatol*. 2007;26:1263–7. <http://dx.doi.org/10.1007/s10067-006-0484-y>. Epub PMID: 17180637 2006 Dec 20.
- Seringeç Akkececi N, Yildirim Cetin G, Gogebakan H, Acipayam C. The C-reactive protein/albumin ratio and complete blood count parameters as indicators of disease activity in patients with Takayasu arteritis. *Med Sci Monit*. 2019;5:1401–9. <http://dx.doi.org/10.12659/MSM.912495>. Published 2019 Feb 22.
- Melikoglu M, Topkarcı Z. Is there a relation between clinical disease activity and acute phase response in Behçet's disease? *Int J Dermatol*. 2014;53:250–4. <http://dx.doi.org/10.1111/ijd.12224>.

24. Balcioglu YH, Kirioglu SS. C-reactive protein/albumin and neutrophil/albumin ratios as novel inflammatory markers in patients with schizophrenia. *Psychiatry Investig.* 2020;17:902–10, <http://dx.doi.org/10.30773/pi.2020.0185>. Epub PMID: 32894927; PMCID: 2020 Sep 9 PMC7538240.
25. Hammad M, Shehata OZ, Abdel-Latif SM, El-Din AMM. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet's disease: which and when to use? *Clin Rheumatol.* 2018;37:2811–7, <http://dx.doi.org/10.1007/s10067-018-4194-z>.
26. Shadmanfar S, Masoumi M, Davatchi F, et al. Correlation of clinical signs and symptoms of Behçet's disease with platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR). *Immunol Res.* 2021;69:363–71, <http://dx.doi.org/10.1007/s12026-021-09194-4>.
27. Qin G, Tu J, Liu L, Luo L, Wu J, Tao L, et al. Serum albumin and C-reactive protein/albumin ratio are useful biomarkers of Crohn's disease activity. *Med Sci Monit.* 2016;22:4393–400, <http://dx.doi.org/10.12659/MSM.897460>.
28. Kim M, Park YG, Park YH. C-reactive protein/albumin ratio as an indicator of disease activity in Behçet's disease and human leukocyte antigen-B27-associated uveitis. *Graefes Arch Clin Exp Ophthalmol.* 2021, <http://dx.doi.org/10.1007/s00417-021-05207-y>. Epub ahead of print. PMID:33929591.
29. Sarhan S, Sherby N, Alian S, Raafat N, El-meligui Y. Association between C reactive protein/albumin ratio and systemic sclerosis disease activity. *Int J Pharm Res.* 2021;13:3, <http://dx.doi.org/10.31838/ijpr/2021.13.03.001>.
30. Costagliola G, Cappelli S, Consolini R. Behçet's disease in children: diagnostic and management challenges. *Therap Clin Risk Manag.* 2020;16:495–507, <http://dx.doi.org/10.2147/TCRM.S232660>.